Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications

The high therapeutic effect of targeted radioisotope/radionuclide therapy (TRT) using α-emitters, especially 225Ac, is attracting attention worldwide. However, the only 225Ac production method that has been put into practical use is extraction from a 229Th generator derived from the nuclear fuel 233...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Processes 2022-06, Vol.10 (6), p.1215
Hauptverfasser: Higashi, Tatsuya, Nagatsu, Kotaro, Tsuji, Atsushi B, Zhang, Ming-Rong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page 1215
container_title Processes
container_volume 10
creator Higashi, Tatsuya
Nagatsu, Kotaro
Tsuji, Atsushi B
Zhang, Ming-Rong
description The high therapeutic effect of targeted radioisotope/radionuclide therapy (TRT) using α-emitters, especially 225Ac, is attracting attention worldwide. However, the only 225Ac production method that has been put into practical use is extraction from a 229Th generator derived from the nuclear fuel 233U, and it is unlikely that this method alone is able to meet future global medical demand. Development towards new 225Ac production methods is in progress. These new 225Ac production methods require the irradiation of 232Th or 226Ra using an accelerator or a nuclear reactor. Global competition has already begun in the race to secure a reliable supply of 232Th and 226Ra, as well as 229Th for the conventional production method. Japan is a “resource-poor country” that depends on foreign countries for most of its needs. As such, it is difficult for Japan to secure raw materials such as 232Th and 226Ra for medical application. In this paper, we look back on our research at the National Institutes for Quantum Science and Technology (QST) in the fields of 225Ac production and 225Ac-labeled pharmaceutical development. We present the history and details of our research from 2011, as well as the development of a collaboration between QST and Nihon Medi-Physics that focuses on research into 225Ac production via 226Ra(p,2n)225Ac reaction using an accelerator. Furthermore, we review the valuable discussion at the 2018 Joint IAEA-JRC Workshop—“Supply of Actinium-225”, an international conference that we participated in. Overall, the statuses of external 225Ac supply, domestic production, and distribution are discussed, as are the latest developments in 225Ac production methods, 225Ac pharmaceuticals, and future prospects for the domestic production of 225Ac in Japan, a country lacking natural resources for medical applications.
doi_str_mv 10.3390/pr10061215
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2679825477</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2679825477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-74c3aa6a225439dd88f9eba6c45af270218882742d7c6a2e70859c32c9a18d383</originalsourceid><addsrcrecordid>eNpNkM1KxDAUhYMoOOhsfIKAO6Gan7ZJlkP9hfGHYVyXa5rOdOwkNWmF2fkQ4gP6JGYYQe_mHi6H-x0OQieUnHOuyEXnKSE5ZTTbQyPGmEiUoGL_nz5E4xBWJI6iXGb5CH3NTDDg9RKDrfCleTet69bG9rh2Hhcb3breO4ufvKsG3TdRuhozlk00rr1bR5nP4Pvjc740uFhC2xq7MAE3FgMu3GB7v8FT0K-NXeAH6AcPLY5MN3gdbVvIvakaHa-Trmuj2DLCMTqooQ1m_LuP0PP11by4TaaPN3fFZJpozrM-EanmADnEPClXVSVlrcwL5DrNoGaCMCqlZCJlldDRZQSRmdKcaQVUVlzyI3S6-9t59zaY0JermMxGZMlyoWT8K0R0ne1c2rsQvKnLzjdr8JuSknJbfflXPf8Bwih3Kg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2679825477</pqid></control><display><type>article</type><title>Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Higashi, Tatsuya ; Nagatsu, Kotaro ; Tsuji, Atsushi B ; Zhang, Ming-Rong</creator><creatorcontrib>Higashi, Tatsuya ; Nagatsu, Kotaro ; Tsuji, Atsushi B ; Zhang, Ming-Rong</creatorcontrib><description>The high therapeutic effect of targeted radioisotope/radionuclide therapy (TRT) using α-emitters, especially 225Ac, is attracting attention worldwide. However, the only 225Ac production method that has been put into practical use is extraction from a 229Th generator derived from the nuclear fuel 233U, and it is unlikely that this method alone is able to meet future global medical demand. Development towards new 225Ac production methods is in progress. These new 225Ac production methods require the irradiation of 232Th or 226Ra using an accelerator or a nuclear reactor. Global competition has already begun in the race to secure a reliable supply of 232Th and 226Ra, as well as 229Th for the conventional production method. Japan is a “resource-poor country” that depends on foreign countries for most of its needs. As such, it is difficult for Japan to secure raw materials such as 232Th and 226Ra for medical application. In this paper, we look back on our research at the National Institutes for Quantum Science and Technology (QST) in the fields of 225Ac production and 225Ac-labeled pharmaceutical development. We present the history and details of our research from 2011, as well as the development of a collaboration between QST and Nihon Medi-Physics that focuses on research into 225Ac production via 226Ra(p,2n)225Ac reaction using an accelerator. Furthermore, we review the valuable discussion at the 2018 Joint IAEA-JRC Workshop—“Supply of Actinium-225”, an international conference that we participated in. Overall, the statuses of external 225Ac supply, domestic production, and distribution are discussed, as are the latest developments in 225Ac production methods, 225Ac pharmaceuticals, and future prospects for the domestic production of 225Ac in Japan, a country lacking natural resources for medical applications.</description><identifier>ISSN: 2227-9717</identifier><identifier>EISSN: 2227-9717</identifier><identifier>DOI: 10.3390/pr10061215</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Actinium ; Cancer therapies ; Clinical trials ; COVID-19 ; Cyclotrons ; Emitters ; FDA approval ; Generic drugs ; Medical research ; Natural resources ; Nuclear fuels ; Nuclear medicine ; Nuclear reactors ; Pharmaceutical industry ; Pharmaceuticals ; Production methods ; Prostate cancer ; R&amp;D ; Radiation ; Radiation therapy ; Radioisotopes ; Radium 226 ; Raw materials ; Research &amp; development ; Self sufficiency ; Thorium isotopes</subject><ispartof>Processes, 2022-06, Vol.10 (6), p.1215</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c335t-74c3aa6a225439dd88f9eba6c45af270218882742d7c6a2e70859c32c9a18d383</citedby><cites>FETCH-LOGICAL-c335t-74c3aa6a225439dd88f9eba6c45af270218882742d7c6a2e70859c32c9a18d383</cites><orcidid>0000-0003-2726-288X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Higashi, Tatsuya</creatorcontrib><creatorcontrib>Nagatsu, Kotaro</creatorcontrib><creatorcontrib>Tsuji, Atsushi B</creatorcontrib><creatorcontrib>Zhang, Ming-Rong</creatorcontrib><title>Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications</title><title>Processes</title><description>The high therapeutic effect of targeted radioisotope/radionuclide therapy (TRT) using α-emitters, especially 225Ac, is attracting attention worldwide. However, the only 225Ac production method that has been put into practical use is extraction from a 229Th generator derived from the nuclear fuel 233U, and it is unlikely that this method alone is able to meet future global medical demand. Development towards new 225Ac production methods is in progress. These new 225Ac production methods require the irradiation of 232Th or 226Ra using an accelerator or a nuclear reactor. Global competition has already begun in the race to secure a reliable supply of 232Th and 226Ra, as well as 229Th for the conventional production method. Japan is a “resource-poor country” that depends on foreign countries for most of its needs. As such, it is difficult for Japan to secure raw materials such as 232Th and 226Ra for medical application. In this paper, we look back on our research at the National Institutes for Quantum Science and Technology (QST) in the fields of 225Ac production and 225Ac-labeled pharmaceutical development. We present the history and details of our research from 2011, as well as the development of a collaboration between QST and Nihon Medi-Physics that focuses on research into 225Ac production via 226Ra(p,2n)225Ac reaction using an accelerator. Furthermore, we review the valuable discussion at the 2018 Joint IAEA-JRC Workshop—“Supply of Actinium-225”, an international conference that we participated in. Overall, the statuses of external 225Ac supply, domestic production, and distribution are discussed, as are the latest developments in 225Ac production methods, 225Ac pharmaceuticals, and future prospects for the domestic production of 225Ac in Japan, a country lacking natural resources for medical applications.</description><subject>Actinium</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>Cyclotrons</subject><subject>Emitters</subject><subject>FDA approval</subject><subject>Generic drugs</subject><subject>Medical research</subject><subject>Natural resources</subject><subject>Nuclear fuels</subject><subject>Nuclear medicine</subject><subject>Nuclear reactors</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceuticals</subject><subject>Production methods</subject><subject>Prostate cancer</subject><subject>R&amp;D</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radioisotopes</subject><subject>Radium 226</subject><subject>Raw materials</subject><subject>Research &amp; development</subject><subject>Self sufficiency</subject><subject>Thorium isotopes</subject><issn>2227-9717</issn><issn>2227-9717</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpNkM1KxDAUhYMoOOhsfIKAO6Gan7ZJlkP9hfGHYVyXa5rOdOwkNWmF2fkQ4gP6JGYYQe_mHi6H-x0OQieUnHOuyEXnKSE5ZTTbQyPGmEiUoGL_nz5E4xBWJI6iXGb5CH3NTDDg9RKDrfCleTet69bG9rh2Hhcb3breO4ufvKsG3TdRuhozlk00rr1bR5nP4Pvjc740uFhC2xq7MAE3FgMu3GB7v8FT0K-NXeAH6AcPLY5MN3gdbVvIvakaHa-Trmuj2DLCMTqooQ1m_LuP0PP11by4TaaPN3fFZJpozrM-EanmADnEPClXVSVlrcwL5DrNoGaCMCqlZCJlldDRZQSRmdKcaQVUVlzyI3S6-9t59zaY0JermMxGZMlyoWT8K0R0ne1c2rsQvKnLzjdr8JuSknJbfflXPf8Bwih3Kg</recordid><startdate>20220617</startdate><enddate>20220617</enddate><creator>Higashi, Tatsuya</creator><creator>Nagatsu, Kotaro</creator><creator>Tsuji, Atsushi B</creator><creator>Zhang, Ming-Rong</creator><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SR</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>JG9</scope><scope>KB.</scope><scope>LK8</scope><scope>M7P</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0003-2726-288X</orcidid></search><sort><creationdate>20220617</creationdate><title>Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications</title><author>Higashi, Tatsuya ; Nagatsu, Kotaro ; Tsuji, Atsushi B ; Zhang, Ming-Rong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-74c3aa6a225439dd88f9eba6c45af270218882742d7c6a2e70859c32c9a18d383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Actinium</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>Cyclotrons</topic><topic>Emitters</topic><topic>FDA approval</topic><topic>Generic drugs</topic><topic>Medical research</topic><topic>Natural resources</topic><topic>Nuclear fuels</topic><topic>Nuclear medicine</topic><topic>Nuclear reactors</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceuticals</topic><topic>Production methods</topic><topic>Prostate cancer</topic><topic>R&amp;D</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radioisotopes</topic><topic>Radium 226</topic><topic>Raw materials</topic><topic>Research &amp; development</topic><topic>Self sufficiency</topic><topic>Thorium isotopes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Higashi, Tatsuya</creatorcontrib><creatorcontrib>Nagatsu, Kotaro</creatorcontrib><creatorcontrib>Tsuji, Atsushi B</creatorcontrib><creatorcontrib>Zhang, Ming-Rong</creatorcontrib><collection>CrossRef</collection><collection>Engineered Materials Abstracts</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Materials Research Database</collection><collection>Materials Science Database</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Processes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Higashi, Tatsuya</au><au>Nagatsu, Kotaro</au><au>Tsuji, Atsushi B</au><au>Zhang, Ming-Rong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications</atitle><jtitle>Processes</jtitle><date>2022-06-17</date><risdate>2022</risdate><volume>10</volume><issue>6</issue><spage>1215</spage><pages>1215-</pages><issn>2227-9717</issn><eissn>2227-9717</eissn><abstract>The high therapeutic effect of targeted radioisotope/radionuclide therapy (TRT) using α-emitters, especially 225Ac, is attracting attention worldwide. However, the only 225Ac production method that has been put into practical use is extraction from a 229Th generator derived from the nuclear fuel 233U, and it is unlikely that this method alone is able to meet future global medical demand. Development towards new 225Ac production methods is in progress. These new 225Ac production methods require the irradiation of 232Th or 226Ra using an accelerator or a nuclear reactor. Global competition has already begun in the race to secure a reliable supply of 232Th and 226Ra, as well as 229Th for the conventional production method. Japan is a “resource-poor country” that depends on foreign countries for most of its needs. As such, it is difficult for Japan to secure raw materials such as 232Th and 226Ra for medical application. In this paper, we look back on our research at the National Institutes for Quantum Science and Technology (QST) in the fields of 225Ac production and 225Ac-labeled pharmaceutical development. We present the history and details of our research from 2011, as well as the development of a collaboration between QST and Nihon Medi-Physics that focuses on research into 225Ac production via 226Ra(p,2n)225Ac reaction using an accelerator. Furthermore, we review the valuable discussion at the 2018 Joint IAEA-JRC Workshop—“Supply of Actinium-225”, an international conference that we participated in. Overall, the statuses of external 225Ac supply, domestic production, and distribution are discussed, as are the latest developments in 225Ac production methods, 225Ac pharmaceuticals, and future prospects for the domestic production of 225Ac in Japan, a country lacking natural resources for medical applications.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/pr10061215</doi><orcidid>https://orcid.org/0000-0003-2726-288X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2227-9717
ispartof Processes, 2022-06, Vol.10 (6), p.1215
issn 2227-9717
2227-9717
language eng
recordid cdi_proquest_journals_2679825477
source MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Actinium
Cancer therapies
Clinical trials
COVID-19
Cyclotrons
Emitters
FDA approval
Generic drugs
Medical research
Natural resources
Nuclear fuels
Nuclear medicine
Nuclear reactors
Pharmaceutical industry
Pharmaceuticals
Production methods
Prostate cancer
R&D
Radiation
Radiation therapy
Radioisotopes
Radium 226
Raw materials
Research & development
Self sufficiency
Thorium isotopes
title Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T08%3A31%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Research%20and%20Development%20for%20Cyclotron%20Production%20of%20225Ac%20from%20226Ra%E2%80%94The%20Challenges%20in%20a%20Country%20Lacking%20Natural%20Resources%20for%20Medical%20Applications&rft.jtitle=Processes&rft.au=Higashi,%20Tatsuya&rft.date=2022-06-17&rft.volume=10&rft.issue=6&rft.spage=1215&rft.pages=1215-&rft.issn=2227-9717&rft.eissn=2227-9717&rft_id=info:doi/10.3390/pr10061215&rft_dat=%3Cproquest_cross%3E2679825477%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2679825477&rft_id=info:pmid/&rfr_iscdi=true